Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 270

1.

Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.

Wan YW, Beer DG, Guo NL.

Lung Cancer. 2012 Apr;76(1):98-105. doi: 10.1016/j.lungcan.2011.09.016. Epub 2011 Nov 1.

2.

Pathway-based identification of a smoking associated 6-gene signature predictive of lung cancer risk and survival.

Guo NL, Wan YW.

Artif Intell Med. 2012 Jun;55(2):97-105. doi: 10.1016/j.artmed.2012.01.001. Epub 2012 Feb 11.

3.

Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.

Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, Vallyathan V, Castranova V, Guo NL.

PLoS One. 2010 Aug 17;5(8):e12222. doi: 10.1371/journal.pone.0012222.

4.

A novel network model identified a 13-gene lung cancer prognostic signature.

Guo NL, Wan YW, Bose S, Denvir J, Kashon ML, Andrew ME.

Int J Comput Biol Drug Des. 2011;4(1):19-39. doi: 10.1504/IJCBDD.2011.038655. Epub 2011 Feb 17.

5.

Confirmation of gene expression-based prediction of survival in non-small cell lung cancer.

Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, Castranova V, Beer DG, Qian Y.

Clin Cancer Res. 2008 Dec 15;14(24):8213-20. doi: 10.1158/1078-0432.CCR-08-0095.

6.

The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.

Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M.

Ann Thorac Surg. 2013 Sep;96(3):962-8. doi: 10.1016/j.athoracsur.2013.05.091. Epub 2013 Aug 8.

PMID:
23932319
7.

Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.

Uzunoglu FG, Kaufmann C, Wikman H, Güngör C, Bohn BA, Nentwich MF, Reeh M, Pantel K, Bockhorn M, Kutup A, Mann O, Izbicki JR, Vashist YK.

Ann Surg Oncol. 2012 Jul;19(7):2159-68. doi: 10.1245/s10434-012-2227-4. Epub 2012 Mar 7.

PMID:
22395975
8.

Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.

Ko E, Lee BB, Kim Y, Lee EJ, Cho EY, Han J, Shim YM, Park J, Kim DH.

Clin Cancer Res. 2013 Mar 1;19(5):1204-12. doi: 10.1158/1078-0432.CCR-12-2848. Epub 2013 Jan 14.

9.

Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.

Sakashita H, Inoue H, Akamine S, Ishida T, Inase N, Shirao K, Mori M, Mimori K.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S590-8. doi: 10.1245/s10434-013-3059-6. Epub 2013 Jun 28. Erratum in: Ann Surg Oncol. 2014 Dec;21 Suppl 4:S783.

PMID:
23812770
10.

Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.

Lu Y, Wang L, Liu P, Yang P, You M.

PLoS One. 2012;7(1):e30880. doi: 10.1371/journal.pone.0030880. Epub 2012 Jan 23.

11.

A prognostic test for adenocarcinoma of the lung from gene expression profiling data.

Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R.

Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):905-10.

12.

Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.

Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, König A, Fernandes O, Karlsson M, Helenius G, Karlsson C, Rahnenführer J, Hengstler JG, Micke P.

Clin Cancer Res. 2013 Jan 1;19(1):194-204. doi: 10.1158/1078-0432.CCR-12-1139. Epub 2012 Oct 2.

13.

Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival.

Sun Z, Wigle DA, Yang P.

J Clin Oncol. 2008 Feb 20;26(6):877-83. doi: 10.1200/JCO.2007.13.1516.

14.
15.

Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.

Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche MH.

Am J Respir Crit Care Med. 2010 Jan 15;181(2):181-8. doi: 10.1164/rccm.200812-1807OC. Epub 2009 Oct 15.

PMID:
19833826
16.

The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.

Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, Kim JH.

J Thorac Oncol. 2013 Feb;8(2):171-8. doi: 10.1097/JTO.0b013e318277a3bb.

PMID:
23287850
17.

Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.

Lee Y, Yoon KA, Joo J, Lee D, Bae K, Han JY, Lee JS.

Carcinogenesis. 2013 Feb;34(2):307-13. doi: 10.1093/carcin/bgs356. Epub 2012 Nov 8.

18.

Gene expression signature predicts recurrence in lung adenocarcinoma.

Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM.

Clin Cancer Res. 2007 May 15;13(10):2946-54.

19.

RANTES expression is a predictor of survival in stage I lung adenocarcinoma.

Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG.

Clin Cancer Res. 2002 Dec;8(12):3803-12.

20.

Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets.

Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN.

PLoS One. 2012;7(9):e45894. doi: 10.1371/journal.pone.0045894. Epub 2012 Sep 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk